On the role of cortical glutamate in obsessive-compulsive disorder and attention-deficit hyperactivity disorder, two phenomenologically antithetical conditions

Acta Psychiatrica Scandinavica

Volumn 102, Issue 6, 2000, Pages 401-413

  Carlsson, Maria L ^a,b  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b Box 431 ^*  (Sweden)

Author keywords

Acetylcholine; Attention deficit hyperactivity disorder; Dopamine; Glutamate; Obsessive compulsive disorder; Prefrontal; Serotonin; Tourette's disorder

Indexed keywords

ACETYLCHOLINE; DOPAMINE; DOPAMINE 1 RECEPTOR; GLUTAMIC ACID; NICOTINIC RECEPTOR; SEROTONIN; SEROTONIN 2A RECEPTOR;

ATTENTION DEFICIT DISORDER; CHOLINERGIC SYSTEM; DOPAMINERGIC SYSTEM; GILLES DE LA TOURETTE SYNDROME; HUMAN; NEUROCHEMISTRY; OBSESSION; PATHOPHYSIOLOGY; PHENOMENOLOGY; PREFRONTAL CORTEX; PRIORITY JOURNAL; REVIEW; SEROTONINERGIC SYSTEM;

ACETYLCHOLINE; ADOLESCENT; ADULT; AGED; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CEREBRAL CORTEX; CHILD; CHILD, PRESCHOOL; DOPAMINE; FEMALE; GLUTAMIC ACID; HUMANS; MALE; MIDDLE AGED; OBSESSIVE-COMPULSIVE DISORDER; SEROTONIN;

EID: 0033647438     PISSN: 0001690X     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1600-0447.2000.102006401.x     Document Type: Review

References (115)

1. Directions of aetiological research on attention deficit hyperactivity disorder
2. Pharmacological therapy of obsessive compulsive disorder
3. Long-term stimulant treatment of children with attention-deficit hyperactivity symptoms
4. Connections, functions and dysfunctions of limbic structures, the prefrontal cortex and hypothalamus
5. Systematic regional differences in the cholinergic innervation of the primate cerebral cortex: Distribution of enzyme activities and some behavioral implications
6. Cingulate cortex of the rhesus monkey: II. Cortical afferents
7. Functional architecture of basal ganglia circuits: Neural substrates of parallel processing
8. Connections of the monkey cingulate cortex
9. Limbic connections of the orbital and medial prefrontal cortex in macaque monkeys
10. Glutamate and aspartate immunoreactive neurons of the rat basolateral amygdala: Colocalization of excitatory amino acids and projections to the limbic circuit
11. Neuropharmacology of methylphenidate and a neural substrate for childhood hyperactivity
12. Anatomy and function of the orbital frontal cortex, II. Function and relevance to obsessive-compulsive disorder
13. Neuroimaging studies of obsessive compulsive disorder
14. Cerebral glucose metabolic rates in obsessive-compulsive disorder
15. Cerebral glucose metabolism in childhood-onset obsessive-compulsive disorder
16. Regional xenon 133 cerebral blood flow and cerebral technetium 99 m HMPAO uptake in unmedicated patients with obsessive-compulsive disorder and matched normal control subjects
17. Functional magnetic resonance imaging of symptom provocation in obsessive-compulsive disorder
18. Caudate glucose metabolic rate changes with both drug and behavior therapy for obsessive-compulsive disorder
19. Neurosurgical therapy of obsessive-compulsive disorder
20. Treatment of obsessive-compulsive disorder by psychosurgery
21. Obsessive compulsive disorder and ventromedial frontal lesions: Clinical and neuropsychological findings
22. Basal ganglia neuropharmacology and obsessive-compulsive disorder: The obsessive-compulsive disorder hypothesis of basal ganglia dysfunction
23. Obsessive-compulsive disorder: A neuroethological perspective
24. Neuroimaging and frontal-subcortical circuitry in obsessive-compulsive disorder
25. Obsessional slowness. Functional studies with positron emission tomography
26. 99mTc-HMPAO uptake in patients with obsessive-compulsive disorder before and during treatment
27. Local cerebral glucose metabolic rates in obsessive-compulsive disorder
28. Obsessive-compulsive disorder: Evidence for basal ganglia dysfunction
29. The cingulate gyrus and human behavior
30. Transient feeling of compulsion caused by hemispheric lesions: Three cases
31. Neurological factors in obsessive-compulsive disorder. Two case reports and a review of the literature
32. Response of obsessive compulsive disorder to carbamazepine in two patients with comorbid epilepsy
33. Temporal lobe epilepsy and obsessive-compulsive symptoms
34. Childhood obsessive-compulsive disorder and cingulate epilepsy
35. Relief of obsessive-compulsive symptoms by LSD and psilocin
36. Successful treatment of obsessive-compulsive disorder with ECT
37. Maintenance ECT for refractory obsessive-compulsive disorder
38. Refractory obsessive compulsive disorder and ECT
39. Obsessive-compulsive disorder responsive to electroconvulsive therapy in an elderly woman
40. Interactions between glutamatergic and monoaminergic systems within the basal ganglia - Implications for schizophrenia and Parkinson's disease
41. Case study: Caudate glutamatergic changes with paroxetine therapy for pediatric obsessive-compulsive disorder
42. Movement disorders associated with the serotonin selective reuptake inhibitors
43. Striatal and nigral neuron subpopulations in rigid Huntington's disease. Implications for the functional anatomy of chorea and rigidity-akinesia
44. Serotonin-glutamate interactions in rat cerebellum: Involvement of 5-HT1 and 5-HT2 receptors
45. Serotonin3 receptor agonists attenuate glutamate-induced firing in rat hippocampal CA1 pyramidal cells
46. Serotonin inhibits epileptiform discharge by activation of 5HT1A receptors in CA1 pyramidal neurons
47. LSD treatment in a severe case of compulsive neurosis
48. Hallucinogen-induced relief of obsessions and compulsions
49. Development of transient obsessive-compulsive symptoms during treatment with clozapine
50. Addition of fluoxetine to clozapine
51. Emergence of obsessive compulsive symptoms during treatment with clozapine
52. Development of obsessive-compulsive symptoms during clozapine treatment
53. Treatment of clozapine-induced obsessive-compulsive symptoms with sertraline
54. Exacerbation of obsessive-compulsive symptoms associated with clozapine
55. Can clozapine trigger OCD?
56. Fluvoxamine treatment in clozapine-induced obsessive-compulsive symptoms in schizophrenic patients
57. Kindling with clozapine: Behavioral and molecular consequences
58. Case study: Emergence of transient compulsive symptoms during treatement with clothiapine
59. Risperidone and obsessive-compulsive symptoms
60. Risperidone, serotonergic mechanisms, and obsessive-compulsive symptoms in schizophrenia
61. Differential response of psychotic and obsessive symptoms to risperidone in an adolescent
62. A case report of risperidone-induced obsessive-compulsive symptoms
63. Treatment of risperidone-induced obsessive-compulsive symptoms with sertraline
64. Risperidone may worsen fluoxetine-treated OCD
65. Risperidone in the treatment of affective illness and obsessive-compulsive disorder
66. Risperidone addition in fluvoxamine-refractory obsessive-compulsive disorder: Three cases
67. Therapeutic effect and safety of adjunctive risperidone in refractory obsessive-compulsive disorder
68. Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder
69. Update on pharmacological management of OCD: Agents and augmentation
70. Risperidone augmentation of serotonin reuptake inhibitors in obsessive-compulsive and related disorders
71. Concurrent locomotor stimulation and decrease in dopamine release in rats and mice after treatment with the competitive NMDA receptor antagonists D-CPPene and CGS 19755
72. The selective 5-HT2A receptor antagonist MDL 100,907 counteracts the psychomotor stimulation ensuing manipulations with monoaminergic, glutamatergic or muscarinic neurotransmission in the mouse - Implications for psychosis
73. Excitation of interneurons in piriform cortex by 5-hydroxytryptamine (5-HT): Blockade by MDL 100, 907, a highly selective 5-HT2A antagonist
74. Hypothesis: Is infantile autism a hypoglutamatergic disorder? Relevance of glutamate - Serotonin interactions for pharmacotherapy
75. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia
76. M100907, A selective 5-HT2A receptor antagonist and a potential antipsychotic drug, facilitates N-methyl-D-aspartate receptor mediated neurotransmission in the rat medial prefrontal cortical neurons in vitro
77. Obsessive-compulsive disorder and basal ganglia dysfunction
78. Probing striatal function in obsessive-compulsive disorder: A PET study of implicit sequence learning
79. Neurotransmission in the rat amygdala related to fear and anxiety
80. Aversive gustatory stimulation activates limbic circuits in humans
81. Elevated growth hormone responses to pyridostigmine in obsessive-compulsive disorder: Evidence of cholinergic supersensitivity
82. Anatomy and function of the orbital frontal cortex, I. Anatomy, neurocircuitry, and obsessive-compulsive disorder
83. The effects of nicotine plus haloperidol compared to nicotine only and placebo nicotine only in reducing tic severity and frequency in Tourette's disorder
84. Transdermal nicotine patch and potentiation of haloperidol in Tourette's syndrome
85. Longlasting improvement of Tourette's syndrome with transdermal nicotine
86. Nicotine and attention in adult attention deficit hyperactivity disorder (ADHD)
87. The role of dopamine in epilepsy
88. Striatal dysfunction in attention deficit and hyperactivity disorder
89. Focal cerebral dysfunction in devlopmental learning disabilities
90. SPECT brain imaging abnormalities in attention deficit hyperactivity disorder
91. High-resolution brain SPECT imaging in ADHD
92. Cerebral glucose metabolism in adults with hyperactivity of childhood onset
93. Functional brain electrical activity mapping in boys with attention-deficit/hyperactivity disorder
94. Rett syndrome, EEG and the motor cortex as a model for better understanding of attention deficit hyperactivity disorder (ADHD)
95. D-serine added to antipsychotics for the treatment of schizophrenia
96. Obsessive-compulsive symptoms following stimulants
97. Motor/vocal tics and compulsive behaviors on stimulant drugs: Is there a common vulnerability?
98. Methylphenidate-induced obsessive-compulsiveness
99. Clinical features distinguishing patients with Tourette's syndrome and obsessive-compulsive disorder from patients with obsessive-compulsive disorder without tics
100. Obsessions in obsessive-compulsive disorder with and without Gilles de la Touretts's syndrome
101. Obsessive compulsive symptoms in Gilles de la Tourette syndrome and obsessive compulsive disorder. Differences by diagnosis and family history
102. The functional neuroanatomy of Tourette's syndrome: An FDG-PET study. I. Regional changes in cerebral glucose metabolism differentiating patients and controls
103. Brain perfusion abnormalities in Gilles de la Tourette's syndrome
104. Asymmetry of basal ganglia perfusion in Tourette's syndrome shown by technetium-99m-HMPAO SPECT
105. Technetium-99m-HMPAO in Tourette's syndrome on neuroleptic therapy and after withdrawal
106. Phenomenological differences appearing with repetitive behaviours in obsessive compulsive disorder and Gilles de la Tourette's syndrome
107. [123I]-CIT SPECT imaging of striatal dopamine transporter binding in Tourette's disorder